Valuation: Natera, Inc.

Market Cap 49.78B 43.14B 40.77B 37.02B 69.38B 4,775B 69.79B 487B 188B 2,422B 187B 183B 7,720B P/E 2026 *
-254x
P/E 2027 * 47,372x
Enterprise Value 48.69B 42.19B 39.88B 36.21B 67.86B 4,671B 68.26B 476B 184B 2,369B 183B 179B 7,552B EV / Sales 2026 *
16.7x
EV / Sales 2027 * 13.9x
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.55%
1 week+4.55%
Current month+7.26%
1 month+11.43%
3 months+56.89%
6 months+74.70%
Current year+50.74%
1 week 324.45
Extreme 324.45
357.14
1 month 310.38
Extreme 310.38
357.14
Current year 181
Extreme 181
357.14
1 year 157.42
Extreme 157.425
357.14
3 years 36.9
Extreme 36.9
357.14
5 years 26.1
Extreme 26.1
357.14
10 years 7.35
Extreme 7.35
357.14
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Sell

Founder

-50,000 0.0347%
02/09/26 Sell

Executive/Senior Manager

-15,160 0.0105%
01/09/26 Sell

Chief Executive Officer

-1,698 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%+4.55%+97.33%+570.56% 49.78B
+0.17%+1.06%+18.40%+60.93% 26.32B
+0.31%+1.24%-11.87%-36.74% 6.89B
-1.74%+6.93%+1.90%+165.80% 5.96B
+1.45%+0.41%+18.03%+62.99% 3.3B
+2.94%+12.65%-19.73%+2,124.20% 2.91B
+0.26%+7.25%+137.05%+40.71% 2.43B
+14.29%+4.91%+36.77%+45.93% 2.26B
+0.97%+1.95%-14.64%-54.60% 1.85B
+2.83%+4.81%+8.18%-21.23% 1.69B
Average +2.00%+4.73%+27.14%+295.86% 10.34B
Weighted average by Cap. -0.27%+3.65%+54.79%+359.71%

Financials

2026 *2027 *
Net sales 2.91B 2.52B 2.38B 2.16B 4.05B 279B 4.08B 28.45B 10.99B 142B 10.93B 10.69B 451B 3.49B 3.02B 2.86B 2.6B 4.86B 335B 4.89B 34.13B 13.19B 170B 13.11B 12.82B 541B
Net income -192M -167M -157M -143M -268M -18.44B -269M -1.88B -726M -9.35B -722M -706M -29.81B 10.98M 9.52M 8.99M 8.17M 15.3M 1.05B 15.39M 107M 41.49M 534M 41.25M 40.33M 1.7B
Net Debt -1.09B -943M -892M -809M -1.52B -104B -1.53B -10.64B -4.11B -52.96B -4.09B -4B -169B -1.41B -1.23B -1.16B -1.05B -1.97B -136B -1.98B -13.84B -5.35B -68.85B -5.32B -5.2B -219B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
16/09/26 $345.34 -1.55% 1,432,954
15/09/26 $350.78 +2.63% 1,775,774
14/09/26 $341.79 +3.91% 1,043,161
11/09/26 $328.93 +0.86% 798,060
10/09/26 $326.14 -1.26% 1,070,696
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
345.34USD
Average target price
344.33USD
Spread / Average Target
-0.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!